Open Label Extension Study With Pramipexole (PPX) in Children With Tourette Syndrome.

Trial Profile

Open Label Extension Study With Pramipexole (PPX) in Children With Tourette Syndrome.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2015

At a glance

  • Drugs Pramipexole (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Adverse reactions; Registrational
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 22 May 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 14 Apr 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2008-000342-32).
    • 14 Apr 2012 Planned number of patients changed from 116 to 120 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top